My work focuses on improving therapeutic approaches for ALL. To accomplish this, we apply molecular, genetic, pharmacologic and immunologic methodologies to identify the factors leading to successful treatment, evaluate the efficacy of novel antileukemic drugs and therapeutic strategies and optimize the standard of care for this disease.